A carregar...
Case-report: EBV driven lymphoproliferative disorder associated with Ruxolitinib
BACKGROUND: Ruxolitinib, a novel inhibitor of Janus kinases 1 and 2, was recently approved for the treatment of myelofibrosis but, recently, attention has been drawn to potential side effects and especially opportunistic infections and virus reactivations. EBV reactivation has not previously been re...
Na minha lista:
| Publicado no: | BMC Hematol |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4498562/ https://ncbi.nlm.nih.gov/pubmed/26167286 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12878-015-0029-1 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|